Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clinical presentation and outcomes in women and men with advanced heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Relationship Between Invasive Hemodynamics and Liver Function in Advanced Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Atrial fibrillation and anticoagulation in patients with breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background. Liraglutide, a glucagon-like peptide-1 agonist, is used for treatment of type 2 diabetes and has beneficial cardiovascular properties. However, treatment increases heart rate (HR) and possibly the risk of cardiovascular events in chronic heart failure (CHF) patients. We investigated potential associations between HR changes and clinical, laboratory and echocardiographic parameters and clinical events in liraglutide treated CHF patients. Methods. This was a sub-study of the LIVE study. CHF patients (N = 241) with a left ventricular ejection fraction ≤45% were randomised to 1.8 mg liraglutide daily or placebo for 24 weeks. Electrocardiograms (N = 117) and readouts from cardiac implanted electronic devices (N = 20) were analysed for HR and arrhythmias. Results. In patients with sinus rhythm (SR), liraglutide increased HR by 8 ± 9 bpm (pulse measurements), 9 ± 9 bpm (ECG measurements) and 9 ± 6 bpm (device readouts) versus placebo (all p<.005). Increases in HR correlated with liraglutide dose (p=.01). HR remained unchanged in patients without SR. Serious cardiac adverse events were not associated with HR changes. Conclusions. During 6 months of treatment, HR increased substantially in CHF patients with SR treated with liraglutide but was not associated with adverse events. The long-term clinical significance of increased HR in liraglutide treated CHF patients needs to be determined.

OriginalsprogEngelsk
TidsskriftScandinavian cardiovascular journal : SCJ
Vol/bind54
Udgave nummer5
Sider (fra-til)294-299
Antal sider6
ISSN1401-7431
DOI
StatusUdgivet - okt. 2020

ID: 59671775